Supreme Court Keeps Mifepristone Access Until May 14, 2026 During Appeal
Justice Alito extended Supreme Court protection for mifepristone access nationwide through May 14, 2026.
Why it matters: Nationwide access to medication abortion remains unchanged while the Supreme Court decides the FDA challenge. Legal and health professionals must navigate ongoing uncertainty as rules remain in flux.
- Mifepristone can be dispensed by mail or at pharmacies nationwide until at least May 14, 2026.
- The stay blocks a Fifth Circuit order that would have suspended mail and telehealth delivery.
- The lawsuit, led by Louisiana, challenges the FDA’s authority and 2023 policies allowing remote prescribing.
- Medication abortions made up nearly two-thirds of all U.S. abortions in 2023.
The U.S. Supreme Court has issued an administrative stay, extending legal protection for current mifepristone access rules through 5 p.m. on May 14, 2026. This keeps pharmacies and telehealth providers authorized to mail prescriptions of mifepristone—an option that the FDA allowed after updating its regulations in 2023.
- This administrative stay temporarily blocks a lower-court order by the Fifth Circuit Court of Appeals. If allowed to take effect, that ruling would have halted pharmacies and telehealth providers from supplying the abortion pill by mail, requiring in-person visits instead.
- The underlying legal challenge comes from Louisiana and other states. They argue the FDA overstepped its authority in easing restrictions and that these changes undermine state-level abortion bans.
- "While mifepristone access returns to where it was on Friday morning, the whiplash and chaos that patients and providers are navigating have already had real consequences for real people’s lives and futures,” said Alexis McGill Johnson, Planned Parenthood Action Fund president.
- ACLU attorney Julia Kaye said, “While this is a positive short-term development, no one can rest easy when our ability to get this safe, effective medication for abortion and miscarriage care still hangs in the balance.”
The FDA approved mifepristone in 2000 and, based on data affirming its safety, removed the in-person prescribing requirement in 2023. In that year, nearly two-thirds of U.S. abortions used medication, underscoring the impact of the Supreme Court's pending decision.
For now, the Supreme Court’s stay maintains the status quo for clinics and patients. However, legal professionals should note that both federal regulatory powers and state abortion laws remain at stake as the underlying lawsuit proceeds through the courts.
By the numbers:
- 2/3 — Share of U.S. abortions using medication in 2023
- 2023 — Year FDA lifted in-person requirements for mifepristone prescriptions
Yes, but: Even with the extension, legal uncertainty persists and changes could come when the Supreme Court rules on the case.
What's next: The Supreme Court’s full review of the FDA authority challenge could bring rule changes or further stays after May 14, 2026.